What term does the FDA use to describe a concern about an excess of adverse events compared to what would be expected with a product's use?

What term does the FDA use to describe a concern about an excess of adverse events compared to what would be expected with a product's use?

• A. Adverse event cluster
• B. Safety signal
• C. Risk spike
• D. Benefit anomaly

Answer: (B)

In pharmacovigilance, a safety signal is the term used by the FDA to describe a concern that adverse events are occurring more often than would be expected given a product’s use. This concept comes from signal detection work, where reports (often from spontaneous adverse event databases like FAERS) are analyzed to see if observed events exceed what’s expected under normal usage. When a potential pattern emerges, it flags a possible association between the product and the adverse event that warrants deeper investigation rather than declaring proven causation. This is why “safety signal” is the best fit—it captures the idea of an early warning that prompts further study, monitoring, or action. Other phrases like ad hoc clusters, sudden spikes in risk, or benefit anomalies aren’t standard FDA terms for this initial alert and don’t convey the structured process of detecting and investigating potential safety issues.

In pharmacovigilance, a safety signal is the term used by the FDA to describe a concern that adverse events are occurring more often than would be expected given a product’s use. This concept comes from signal detection work, where reports (often from spontaneous adverse event databases like FAERS) are analyzed to see if observed events exceed what’s expected under normal usage. When a potential pattern emerges, it flags a possible association between the product and the adverse event that warrants deeper investigation rather than declaring proven causation. This is why “safety signal” is the best fit—it captures the idea of an early warning that prompts further study, monitoring, or action. Other phrases like ad hoc clusters, sudden spikes in risk, or benefit anomalies aren’t standard FDA terms for this initial alert and don’t convey the structured process of detecting and investigating potential safety issues.